“Is Curing Patients a Sustainable Business Model?” Goldman Sachs Analysts Askhttps://blogs.mercola.com:443/sites/vitalvotes/archive/2018/04/15/_1C20_is-curing-patients-a-sustainable-business-model_1D20_-goldman-sachs-analysts-ask.aspxAs reported by CNBC , Goldman Sachs analysts are questioning the long-term profitability of “one shot cures” using gene therapy, gene editing and genetically-engineered cell therapy. In a report titled “The Genome Revolution,”enCommunityServer 2008.5 SP1 (Debug Build: 31106.3070)